Menu Close

FDA approval of controversial Alzheimer’s drug could delay discovery of more promising treatments

The U.S. Food and Drug Administration (FDA) recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer’s disease. But approval of the drug has provoked mixed reactions from the scientific community.

Generated by Feedzy